DMARD De-escalation in Controlled RA Raises Flares, Not Safety Benefit
This meta-analysis gives rheumatology pharmacists time-stratified flare and radiographic risk estimates to counsel patients weighing tapering versus withdrawal of disease-modifying antirheumatic drugs.
📅 Journal publication: Oct 2026·Last updated: Oct 12, 2026
DMARD tapering raises flare risk in rheumatoid arthritis.
DMARD tapering may reduce treatment burden in rheumatoid arthritis (RA), but its impact on disease control and adverse events (AEs) is unclear. DMARD tapering increased flare risk, especially for biologic DMARDs (bDMARDs) (RR 1.56), and tapering or withdrawal led to radiographic progression. DMARD tapering needs careful consideration in RA due to increased flare risk and progression; withdrawal should be avoided. Cautiously approach DMARD tapering in controlled RA due to flare and progression risks.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Citation:Zhang X, Pandey RK, Luo X, et al. Temporal Patterns of Outcomes After DMARD Tapering or Withdrawal in Rheumatoid Arthritis With Sustained Disease Control: A Systematic Review and Meta-Analysis. Clinical and translational science. 2026;19(10):e70740. doi:10.1111/cts.70740
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.